Neuropathic Pain Market Size, Share & Industry Analysis, By Drug Class (Anticonvulsants, Tricyclic Antidepressants (TCA), Opioids, Capsaicinoids, and Others), By Application (Diabetic Neuropathy, Chemotherapy Induced Neuropathy, Sciatic Neuropathy, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2024-2032

The global neuropathic pain market size was valued at USD 7.37 billion in 2023. The market is projected to grow from USD 7.79 billion in 2024 to USD 14.05 billion by 2032, exhibiting a CAGR of 7.7% during the forecast period. North America dominated the neuropathic pain market with a market share of 49.93% in 2023.

Neuropathic or nerve pain is caused due to damage or dysfunction of the nervous system. This type of pain is mostly chronic and hinders the normal daily activity of the patients. Treatment option for neuropathic pain management includes medications, implantable medical devices, and surgery.

Neuropathy pain therapeutics, such as gabapentin and capsaicin, are quite effective in nerve pain management. Patients who have diabetes, shingles, or undergoing chemotherapy are more prone to nerve pain. Therefore, the growing burden of these conditions has been fueling the demand for effective nerve pain therapeutics.

• For instance, as per the data published and updated by the Centers for Disease Control and Prevention (CDC) in April 2024, 1 out of 3 individuals in the U.S. suffer from shingles at least once in their lifetime. The risk of the disease increases in the geriatric population, and individuals with weaker immune systems are prone to it.

During the COVID-19 pandemic in 2020, neuropathy pain therapeutics experienced a decline in its revenue due to the implication of lockdown, which restricted the population from visiting the doctors for the treatment of these types of pain, as the hospital visits were reduced to control the spread of the virus. However, in 2021 and 2022, the market experienced significant growth due to the increased burden of patients suffering from these type of pain and the increased number of patients visiting hospitals and clinics.

Neuropathic Pain Market Trends

Market Players Have Been Emphasizing R&D for Novel Therapeutics Development

The increasing burden of neuropathic pain among patients who have cancer or diabetes or have gone through certain surgeries has increased the demand for effective treatment options. To fulfill this increasing demand, market players have increased their focus on novel and effective therapeutics development to manage neuropathy pain effectively. 

• For instance, Eli Lilly and Company initiated a phase 2 clinical trial in October 2024 to study the efficacy of its LY3848575 drug candidate for distal sensory polyneuropathy pain management. The expected completion of the study is in September 2026.


• Similarly, Shanghai SIMR Biotechnology Co., Ltd. initiated a phase 2 clinical trial in August 2024 to study the safety and efficacy of its drug candidate SR750, non-steroidal anti-inflammatory drugs (NSAIDs) indicated for the treatment of trigeminal neuralgia. The expected completion date of the clinical trial is in October 2025.

The launch of these therapeutics will increase the availability of effective pain management options and will also fuel the market growth over the forecast period.

Neuropathic Pain Market Growth Factors

Growing Burden of Chronic Diseases Responsible for Neuropathic Pain has been Fueling the Demand for Effective Therapeutics

Neuropathic pain is often associated with diseases, such as cancer, diabetes, multiple sclerosis, kidney diseases, and shingles. Therefore, the growing burden of these diseases has been fueling the risk of nerve pain. 

• For instance, as per the data published by Healthline in November 2023, in the U.S., around 13.1% of women in the age group of 50 to 64 had osteoporosis. As per the same source, 27.5% of women aged 65 and above had osteoporosis.


• Moreover, according to the data published by the International Diabetes Federation, in 2021, globally, around 10.5% of the individuals between the age group of 20 to 79 years had diabetes. Also, this prevalence of diabetes is estimated to experience a growth of 46% by 2045.

The high burden of these diseases has also been fueling the occurrence of nerve pain among these patients.

• For instance, as per the study published by the Iberoamerican Journal of Medicine in 2021, the prevalence of diabetic neuropathy among the studied diabetes population of the Northern part of India was 42.0%

The increasing burden of diabetic neuropathy has also been fueling the demand for effective pain management options. To fulfil this, market players have increased their focus on new product launches.

• In February 2023, Anglo-French Drugs & Industries Ltd. launched AFD-NP for neuropathy pain management in India.

Therefore, the growing demand for nerve pain management therapeutics, along with the increasing focus of the market players on new product launches, has been fueling the neuropathic pain market growth.

RESTRAINING FACTORS

Side Effects associated with the Use of Neuropathic Pain Medication has been Restricting the Market Growth

The growing burden of nerve pain due to diabetes, chemotherapy, and other nervous system injuries has been fueling the demand for effective therapeutics.

However, there are certain side effects associated with the use of nerve pain therapeutics, such as dizziness, nausea, dry mouth, and edema, among others, restrict patients from adopting these therapeutics.

• For instance, side effects associated with the use of pregabalin as pain management include dizziness, tiredness, dry mouth, edema, and blurred vision. Similarly, gabapentin can cause tiredness, dizziness, confusion, and peripheral edema. Also, other neuropathic therapeutics, such as antidepressants and anti-seizure medicines, can cause dry mouth, drowsiness, and blurred vision.

All the factors mentioned above restrict the patients from taking these therapeutics. Due to this, patients prefer going for alternate options, such as devices and surgeries for pain management.

Neuropathic Pain Market Segmentation Analysis

By Drug Class Analysis

Strong Availability of Anticonvulsant Drugs and Increasing Prevalence of Neuropathic Pain Fueled Segment Growth

On the basis of drug class, the global market is segmented into anticonvulsants, tricyclic antidepressants (TCA), opioids, capsaicinoids, and others.

The anticonvulsants segment dominated the market in 2023. The segment’s dominance is attributed to the increasing demand for effective pain management options for diabetic neuropathy along with the strong availability of anticonvulsant drugs, such as Gralise, Horizant, Neurontin, Lyrica, and OXTELLAR XR, in the market.

Moreover, the others segment is expected to grow at the fastest CAGR during the forecast period. The segment’s growth is attributed to the increasing focus of the market players on conducting clinical trials for the development of novel therapeutics.

• For instance, Algiax Pharmaceuticals GmbH initiated a phase 2 clinical trial in July 2020 to study the safety and efficacy of AP-325 in managing post-surgical neuropathy pain. The expected completion of the study is in March 2025.

By Application Analysis

Increasing Prevalence of Cancer Fueled Demand for Effective Chemotherapy Induced Neuropathy Pain Management

Based on the application, the market is segmented into diabetic neuropathy, chemotherapy induced neuropathy, sciatic neuropathy, and others.

The chemotherapy induced neuropathy segment dominated the market by accounting for the major proportion of the global neuropathic pain market share in 2023. The segment’s dominance is attributed to the growing burden of cancer, which has been increasing the number of patients undergoing chemotherapy, thereby increasing the chemotherapy induced neuropathy.

• For instance, as per the data published by the World Health Organization (WHO), in 2022, around 20 million new cancer cases were diagnosed globally. Moreover, the number of new cancer cases is expected to reach 29.9 million by 2040.

Furthermore, the diabetic neuropathy segment is expected to grow at the fastest CAGR during the forecast period. The segment’s growth is attributed to the increased focus of the pharmaceutical and biopharmaceutical industry on research and development of novel therapeutics.

By Route of Administration

Strong Presence of Neuropathy Pain Therapeutics in Oral Forms Boosted Segement’s Dominance

On the basis of the route of administration, the market is bifurcated into oral and parenteral.

The oral segment dominated the market in 2023 and is expected to grow at the fastest CAGR during the forecast period. The segment’s dominance is attributed to the availability of a variety of oral therapeutics for nerve pain management, such as Lyrica, OXTELLAR XR, and Trileptal, among others.

Furthermore, the parenteral segment is expected to grow at a substantial CAGR during the forecast period. The segment’s growth is attributed to the increasing focus of pharmaceutical and biotechnology companies on the development of effective novel therapeutics.

• For instance, Noema Pharma AG initiated a phase 2 clinical trial in January 2022 to study the safety and efficacy of phenylimidazoles for treating trigeminal neuralgia through injection. The expected clinical study completion is in January 2026.

By Distribution Channel Analysis

Retail Pharmacy Dominated the Market Due to the Easy Availability of Medications

Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

Retail pharmacy dominated the global neuropathic pain therapeutics market in 2023. The segment’s dominance is attributed to the increasing demand for topical nerve pain medications, such as Elavil and AneCream5, which are easily available at retail pharmacies.

The online pharmacy segment is expected to grow at the fastest CAGR during the forecast period. The segment's growth during the forecast period is attributed to the increasing availability of prescription as well as off-label drugs on online channels. Moreover, the increasing preference of individuals to buy products conveniently without actually visiting the stores has also been fueling the segment’s growth.

REGIONAL INSIGHTS

Based on geography, the neuropathic pain market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America dominated the market in 2023, accounting for USD 3.68 billion of the global market. The high growth of the market in North America is attributed to the strong presence of market players, such as Almatica, Azurity Pharmaceuticals, Inc., Pfizer Inc., and Viatris Inc., among others in the region. Furthermore, increasing awareness regarding neuropathic pain has been fueling the demand for effective therapeutics, thereby fueling the market growth in the region. 

The market in Europe is expected to grow at a substantial CAGR during the forecast period due to the growing burden of cancer and diabetes in European countries.

• For instance, according to the data published by The British Diabetic Association in May 2024, in the U.K., around 4.3 million people are living with diabetes. 


• Moreover, as per the data published by the European Commission (EC), in Europe, the incidence of cancer was estimated to be around 2.74 million in 2022. This number is expected to reach 3.25 million by 2040.

The Asia Pacific market is expected to grow at a significant CAGR during the forecast period. The growth of the market in the region is attributed to the increasing focus of the pharmaceutical industry on R&D activities for the development of novel therapeutics. 

• For instance, in May 2024, Haisco Pharmaceutical Group Co., Ltd. initiated a phase 3 clinical trial in China to study the safety and efficacy of its drug candidate, HSK16149. The expected completion of the clinical trial is in July 2027.

The markets in Latin America and the Middle East & Africa are expected to grow at a substantial CAGR in the coming years. The high growth rate in these regions is attributed to the growing burden of chronic diseases and rising awareness about the therapeutics that effectively manage nerve pain.

KEY INDUSTRY PLAYERS

Increasing Focus of the Market Players on Partnerships and Acquisitions to Enhance their Product Offerings 

Market players, such as Novartis AG, Pfizer Inc., and Viatris Inc., are among the major players, accounting for a significant share of the global market. The significant presence of these companies in the market is attributed to their focus on the expansion of product offerings for nerve pain management. 

• For instance, in July 2023, Novartis AG acquired DTx Pharma, the U.S.-based, preclinical-stage biotechnology company, with an aim to enhance its R&D to develop siRNA therapeutics for neurology indications.

Moreover, other players, such as Almatica Pharma LLC, Accord Healthcare, and Abbott, among others, have been focusing on new product launches to enhance their presence in the market. 

• For instance, in May 2022, Almatica Pharma LLC announced the approval of Citalopram 30mg by the Food and Drug Administration (FDA). This drug is a selective serotonin reuptake inhibitor (SSRI) antidepressant that has shown effectiveness in managing neuropathic pain.

LIST OF TOP NEUROPATHIC PAIN COMPANIES:

• Almatica (U.S.)


• Azurity Pharmaceuticals, Inc. (U.S.)


• Pfizer Inc. (U.S.)


• Viatris Inc. (U.S.)


• Supernus Pharmaceuticals, Inc. (U.S.)


• Novartis AG (Switzerland)


• Accord Healthcare (U.K.)


• Focus Health Group (U.S.)


• Amneal Pharmaceuticals LLC (U.S.)


• Abbott (U.S.)


• Teva Pharmaceutical Industries Ltd. (Israel)

KEY INDUSTRY DEVELOPMENTS:

• May 2024 – Lexicon Pharmaceuticals, Inc. selected Medidata, a clinical trial solution provider, to provide services to the company in the Phase 2b clinical study of LX9211, which indicated diabetic neuropathy pain management.


• April 2024 – Vertex Pharmaceuticals Incorporated announced new advancements in its product Suzetrigine, an oral selective NaV1.8 pain signal inhibitor indicated for diabetic neuropathy pain management. This therapeutic can be the first new class of medicine for acute and neuropathic pain.


• September 2023 – Azurity Pharmaceuticals, Inc. acquired Slayback Pharma with the aim of increasing R&D for new product development.


• June 2023 – Novo Nordisk A/S entered into a negotiation to acquire BIO JAG, BIOCORP’s main shareholder. With this acquisition, the company aimed to enhance its drug-delivery device portfolio for chronic diseases.


• June 2022 – Almatica Pharma LLC announced the launch of Venlafaxine Extended-Release Tablets 112.5 mg, an antidepressant that has shown effectiveness in managing neuropathic pain.

REPORT COVERAGE

The global neuropathic pain market report provides a detailed competitive landscape and market insights. It also includes key insights, such as top industry developments covering partnerships, mergers, and acquisitions. Additionally, it focuses on key points, such as new solution launches in the market. Furthermore, the report covers regional analysis of different market segments, profiles of key market players, market trends, and the impact of COVID-19 on the market. The report consists of quantitative and qualitative insights that have contributed to the market's growth.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 7.7% from 2024-2032
Unit	Value (USD billion)
Segmentation	By Drug Class Anticonvulsants Tricyclic Antidepressants (TCA) Opioids Capsaicinoids Others
By Application Diabetic Neuropathy Chemotherapy Induced Neuropathy Sciatic Neuropathy Others
By Route of Administration Oral Parenteral
By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy
By Region North America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country) U.S. Canada Europe (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region) U.K. Germany France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and BY Country/Sub-region) Japan China Australia India Southeast Asia Rest of Asia Pacific Latin America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region) South Africa GCC Rest of Middle East & Africa